ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BeOne Medicines AG (ONC) is not a strong buy for a beginner investor with a long-term focus at this time. While the company has a strong product pipeline and some positive analyst sentiment, the lack of recent positive news, declining financial performance, and hedge fund selling trends suggest caution. Additionally, technical indicators and options data do not provide a compelling entry point currently.
The MACD is positive but contracting, RSI is neutral at 30.648, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 313.427, with key support at 302.066 and resistance at 324.788. Overall, the technical indicators suggest a neutral stance.
Analysts highlight a strong product pipeline, including Brukinsa, and potential momentum from deal activity in the biotech sector. Recent price target increases from Guggenheim, RBC Capital, and Barclays reflect some optimism.
Hedge funds are aggressively selling the stock, with a 7307.41% increase in selling activity. Financial performance has deteriorated significantly, with net income and EPS showing sharp declines. No recent news or congress trading data to provide additional support.
In Q3 2025, revenue grew by 41% YoY to $1.41 billion, but net income dropped by -202.88% YoY to $124.84 million, and EPS fell by -188.89% YoY to 0.08. Gross margin improved slightly to 86.09%. The financial performance indicates revenue growth but significant profitability challenges.
Analysts have mixed views. Truist and Wolfe Research maintain positive ratings with price targets of $411 and $340, respectively, citing strong product potential. However, Jefferies downgraded the stock to Hold with a price target of $290, citing limited upside and slower growth for future assets.
